Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALEN and CRISPR/Cas9 for HPV-related CIN I
NCT03057912Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2018
- Primary completion
- Nov 2018
- Modality
- Gene Silencing, CRISPR-Cas9, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label trial of TALEN-HPV E6/E7 and CRISPR/Cas9-HPV E6/E7 in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (3 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Number of participants with Adverse Events at 6 months. Status: unknown.
02
Drugs
TALEN-HPV E6/E7CRISPR/Cas9-HPV E6/E7
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT03057912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057912.